A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Smith, Eric J ^a   Olson, Kara ^a   Haber, Lauric J ^a   Varghese, Bindu ^a   Duramad, Paurene ^a   Tustian, Andrew D ^a   Oyejide, Adelekan ^a   Kirshner, Jessica R ^a   Canova, Lauren ^a   Menon, Jayanthi ^a   Principio, Jennifer ^a   MacDonald, Douglas ^a   Kantrowitz, Joel ^a   Papadopoulos, Nicholas ^a   Stahl, Neil ^a   Yancopoulos, George D ^a   Thurston, Gavin ^a   Davis, Samuel ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIGEN; CD3 ANTIGEN; CYTOKINE;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; CHEMISTRY; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; IMMUNOPHENOTYPING; ISOLATION AND PURIFICATION; KNOCKOUT MOUSE; MACACA FASCICULARIS; METABOLISM; MOLECULAR GENETICS; MOLECULAR MODEL; MOUSE; NEOPLASMS; PATHOLOGY; PHENOTYPE; PROTEIN CONFORMATION; SCID MOUSE; SEQUENCE ALIGNMENT; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD3; B-LYMPHOCYTES; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOPHENOTYPING; MACACA FASCICULARIS; MICE; MICE, KNOCKOUT; MICE, SCID; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHENOTYPE; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84949681670     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17943     Document Type: Article

References (20)

1. Spiess, C., Zhai, Q. & Carter, P. J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. 67, 95-106 (2015).
2. Ridgway, J. B., Presta, L. G. & Carter, P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-21 (1996).
3. Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637-46 (2010).
4. Lindhofer, H., Mocikat, R., Steipe, B. & Thierfelder, S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155, 219-25 (1995).
5. Staerz, U. D. & Bevan, M. J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. USA 83, 1453-7 (1986).
6. Burges, A. et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin. Cancer Res. 13, 3899-905 (2007).
7. Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-7 (2008).
8. Jendeberg, L. et al. Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A. J. Immunol. Methods 201, 25-34 (1997).
9. Deisenhofer, J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8 - A resolution. Biochemistry 20, 2361-70 (1981).
10. Clackson, T., Hoogenboom, H. R., Griffiths, A. D. & Winter, G. Making antibody fragments using phage display libraries. Nature 352, 624-8 (1991).
11. Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl. Acad. Sci. USA 111, 5153-8 (2014).
12. Graille, M. et al. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc. Natl. Acad. Sci. USA 97, 5399-404 (2000).
13. Ghose, S., Allen, M., Hubbard, B., Brooks, C. & Cramer, S. M. Antibody variable region interactions with Protein A: implications for the development of generic purification processes. Biotechnol. Bioeng. 92, 665-73 (2005).
14. FDA, Rituxan (rituximab) Label-103705s5311lbl.pdf. (2010) Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2010/103705s5311lbl.pdf. (Accessed: 10/28/2015)
15. NIH, A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20 + B-Cell Malignancies. (2014) Available at: https://clinicaltrials.gov/ct2/show/NCT02290951. (Accessed: 10/28/2015)
16. Spiess, C. et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct halfantibodies. Nat. Biotechnol. 31, 753-8 (2013).
17. Fischer, N. et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat. Commun. 6, 6113 (2015).
18. Lichtenfels, R., Biddison, W. E., Schulz, H., Vogt, A. B. & Martin, R. CARE-LASS (calcein-release-assay), an improved fluorescencebased test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 172, 227-39 (1994).
19. Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-89 (2005).
20. Lu, H. et al. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew. Chem. Int. Ed. Engl. 53, 9841-5 (2014).